New study of safety and efficacy of combination therapy in patients with rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a cancer made up of cells that normally develop into muscles that are attached to bones. RMS is a rare but aggressive cancer and is the most common soft tissue cancer in children. Patients with relapsed or refractory RMS have not seen improvements in survival over the past several decades. Christine M. Heske, M.D., Assistant Clinical Investigator in the Pediatric Oncology Branch, is leading a study of a new drug combination of ganitumab and dasatinib for patients with RMS to test if it can slow tumor growth.
Ganitumab blocks an abnormally activated signaling pathway that helps tumor cells to grow, while dasatinib blocks the action of a protein that, when activated, can contribute to drug resistance and signal cancer cells to multiply. Dr. Heske is hopeful that it will address the problem of therapeutic resistance to IGF-1R antibody therapy and improve outcomes for patients with rhabdomyosarcoma who have not responded to other treatments. View more information on this trial.